Hindustan Life Sciences (I) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.20 M
as on 24-10-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
as on 24-10-2024
- Revenue 3.19%
(FY 2023)
- Profit 16.27%
(FY 2023)
- Ebitda 1.98%
(FY 2023)
- Net Worth 9.56%
(FY 2023)
- Total Assets -18.48%
(FY 2023)
About Hindustan Life Sciences (I)
The Corporate was formerly known as Hindustan Life Sciences (I) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹1.00 M.
Lalit Mishra, Ranjana Mishra, and Rishav Mishra serve as directors at the Company.
- CIN/LLPIN
U33110MP2014PLC032981
- Company No.
032981
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
30 Jul 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Hindustan Life Sciences (I) Limited offer?
Hindustan Life Sciences (I) Limited offers a wide range of products and services, including Common Disease Medicines, Eye Drops, Chemical Reagents & Catalysts, Organic Compounds.
Who are the key members and board of directors at Hindustan Life Sciences (I)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lalit Mishra  | Director | 30-Jul-2014 | Current |
| Ranjana Mishra | Director | 30-Jul-2014 | Current |
| Rishav Mishra | Director | 20-Sep-2021 | Current |
Financial Performance of Hindustan Life Sciences (I).
Hindustan Life Sciences (I) Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.19% increase. The company also saw a substantial improvement in profitability, with a 16.27% increase in profit. The company's net worth moved up by a moderate rise of 9.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hindustan Life Sciences (I)?
In 2023, Hindustan Life Sciences (I) had a promoter holding of 97.50% and a public holding of 2.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Feb 2023 | ₹1.00 M | Open |
How Many Employees Work at Hindustan Life Sciences (I)?
Unlock and access historical data on people associated with Hindustan Life Sciences (I), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hindustan Life Sciences (I), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hindustan Life Sciences (I)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
